In separate clinical trials, two treatments showed promise that they could help patients with one of the most dire diagnoses ...

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly ...

Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.

Former Sen. Ben Sasse (R–Neb.), who previously served as president of the University of Florida, revealed in late December ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

The overall risk of malignancy in pancreatic cysts may be as low as 0.5 to 1.5%, and the annual risk of progression is 0.5%. 7,15 Conversely, studies estimate that 15% of all pancreatic ...

Several factors can influence a person’s life expectancy if they experience recurrence of pancreatic cancer, including the location of recurrence, a person’s treatment, and their tumor grading, size, ...